Richter MD, et al. - Between January 1, 2011, and March 1, 2018, authors estimated the prevalence, clinical presentation, and management of rheumatic immune-related adverse effects (Rh-irAEs) from immune checkpoint inhibitor (ICI) therapy among 1293 subjects who received any ICI. Researchers noted commonly polyarticular inflammatory arthritis and glucocorticoid treatment was needed in 76% cases. They noted that 15% got disease-modifying antirheumatic drugs whereas ICI therapy had to be discontinued in 9% cases. They also recorded other syndromes like connective tissue diseases, vasculitis, polymyalgia rheumatica–like syndrome, and flare of preexisting rheumatic disease. They found 71% of cases with long courses of immunosuppressive treatment.